Biotechnology

BIOCYTOGEN-B

Bioceanus Pharmaceutical Clarifies Shareholders' Meeting Circular Errors and Seeks Credit Facilities

Bioscience-B Plans to Invest 1.6 Billion in New Facilities

BIOCYTOGEN-B released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue HKD 490.97 M, actual EPS HKD 0.2607

Biosettia Reports Scaled Profitability in 2025 Annual Report

BIOCYTOGEN-B to Release FY2026 Q1 Earnings on April 27 After-Market (BJT)

Biocytogen Announces 2025 Performance and License Agreement with Taisho Pharmaceutical

Innovative Drug Sector Benefits Baolisaite Bio's Earnings Report

Biosyntech Partner NEOK Bio's NEOK002 Receives FDA Clinical Trial Approval

BiosynerTech Announces Audited Annual Performance for 2025

Bioscience reported significant revenue and net profit growth in 2025 without dividend distribution

BIOCYTOGEN-B to Release FY2025 Earnings on March 26 After-Market (BJT), Forecast Revenue HKD 1.61 B, EPS HKD 0.3892

Biotium Announces Significant 2025 Earnings Growth and Promotes Licensing Collaborations

BIOCYTOGEN-B released FY2025 9 Months earnings on February 26 (BJT), actual revenue HKD 1.087 B, actual EPS HKD 0.2983

BIOCYTOGEN-B released FY2025 Q3 earnings on February 26, 2026 (BJT) with actual revenue of HKD 349.72 M and EPS of HKD 0.1825

BIOCYTOGEN-B released FY2025 annual earnings on February 26 After-Market (BJT), actual revenue HKD 1.507 B (forecast HKD 1.61 B), actual EPS HKD 0.4699 (forecast HKD 0.3892)

BIOCYTOGEN-B released FY2025 Q4 earnings on February 26 After-Market BJT, actual revenue HKD 486.99 M, actual EPS HKD 0.1534

Biocean Chart Announces Significant Revenue and Net Profit Growth in 2025

Biomabot Predicts Net Profit Increase of 384% to 444% in 2025

Biosciant-B to Increase Investment in Jiangsu Biosciant via Debt-to-Equity Conversion

Guotai Haitong Securities Upgrades Biocytogen-B to 'Outperform'

HUISHENG INTL

AEC GROUP

I.CENTURY HLDG

KOS TALENT GP

CHINA TRAVEL HK

ASIAPAC FIN INV

RIVERINE CHINA

ZXZN QI-HOUSE

XL2CSOPHYNIX

VSING

688796

02315

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has clarified a clerical error in its AGM circular regarding a special resolution for credit facilities. The company plans to seek a consolidated bank credit line of up to RMB1.5 billion and provide guarantees for its subsidiaries' loans. This move aims to enhance financial flexibility and risk management, concentrating credit exposure at the group level. The company focuses on drug research and development and operates through its parent and subsidiaries, utilizing bank credit for funding needs.

Tip Ranks

Biocytogen

Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees

Biocytogen Pharmaceuticals (Beijing) reported Q1 2026 revenue of ¥433.1 million and basic EPS of ¥0.23, reflecting significant year-over-year earnings growth and a net margin increase to 18.6% from 7.6%. The trailing twelve-month net income reached ¥290.5 million, supporting a bullish outlook despite concerns over profitability stability. The stock trades at HK$51.70 with a P/E of 69.3x, above industry averages, raising questions about valuation. Investors are encouraged to consider long-term trends and the company's growth potential amidst current market narratives.

Simplywall

Biocytogen Pharmaceuticals Beijing Q1 Margin Expansion Reinforces Bullish Earnings Narratives

02656

02637

01361

02650

06166

03317

00679

02513

01057

160 HEALTH(02656) fell 22.67%, with a trading turnover 671.5 Million HKD, and a year-to-date fell 60.5%. HAIXI PHARMA(02637) fell 21.01%, with a trading turnover 418.0 Million HKD, and a year-to-date rose 63.1%. 361 DEGREES(01361) fell 20.52%, with a trading turnover 978.7 Million HKD, and a year-to-date fell 9.2%.

Top Gainers&Losers

160 HEALTH

HAIXI PHARMA

361 DEGREES

ZHIDA TECH

XUNCE

ASIA TELE-NET

KNOWLEDGE ATLAS

ZHEJIANG SHIBAO

Top 10 HK Stock Losers (4.28)

516500

510660

512010

159102

588130

Biocytogen has partnered with Sihuan Pharmaceutical to develop new therapeutics, focusing on weight loss and other disease areas. The collaboration combines Biocytogen's human antibody discovery platform with Sihuan's drug development and commercialization expertise. This strategic alliance aims to accelerate the clinical and commercial progression of promising antibody therapeutics, leveraging advanced technologies and integrated platforms. Biocytogen's CEO, Dr. Yuelei Shen, expressed enthusiasm for the partnership, highlighting its potential to enhance their joint efforts in drug discovery and development.

Pharmaceutical Technology

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Biocytogen and Sihuan partner to advance new therapeutics for weight loss

06636

00568

09973

03625

00175

02186

02333

00290

EXTREME VISION(06636) rose 20.12%, with a trading turnover 255.1 Million HKD, and a year-to-date rose 149.3%. ZHIDA TECH(02650) rose 16.75%, with a trading turnover 19.3 Million HKD, and a year-to-date fell 21.7%. SHANDONG MOLONG(00568) rose 16.37%, with a trading turnover 3.9 Billion HKD, and a year-to-date rose 191.5%.

EXTREME VISION

SHANDONG MOLONG

CHERY AUTO

FOURSEMI

GEELY AUTO

LUYE PHARMA

GWMOTOR

GOFINTECH QUANT

Top 10 HK Stock Gainers (4.2)

02661

513120

AI healthcare stocks in the Hong Kong market surged, with Medlive Technologyrising over 9%. Easy Healthand Bio-Thera Solutions-Bboth increased by more than 6.5%, while Ark Healthclimbed over 5%, and MicroPort Roboticssaw an increase of more than 4%.

CoinLive

QINGSONG HEALTH

GF CSI HK Innovative Drugs Industry ETF(QDII)

MEDLIVE

MircroPort Medbot-B

Dacheng CSI All Share Health Care Equipment and Services ETF

FANGZHOU JIANKE

First Trust NYSE Arca Biotech Index Fd

AI Healthcare Stocks Surge in Hong Kong Market

BIOCYTOGEN-B announced its full-year results for the year ended December last year, with a revenue of RMB 1.379 billion, an increase of 40.6% year-on-year. The net profit was RMB 173 million, an increase of 416.4% year-on-year; earnings per share were RMB 0.43. No dividend was declared

AASTOCKS

"Performance" BIOCYTOGEN-B's annual net profit rises 416.4% to RMB 173 million

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has published its audited annual results for the year ending December 31, 2025, reviewed by the board’s audit committee. The full annual report will be available by the end of April 2026. The announcement confirms the board's current composition, indicating governance stability. The latest analyst rating for the stock (HK:2315) is a Hold with a price target of HK$48.00. Biocytogen focuses on pharmaceutical R&D and is listed in Hong Kong under stock code 2315, with a market cap of HK$22.61B.

Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report

BIOCYTOGEN-B(02315.HK)